drugset / Trial / NCT05084651

Drug-drug Interaction Study of Ganaplacide and Lumefantrine With Itraconazole

NCT05084651

NaSequentialOpen-labelTreatment

Summary

The study will assess the effect of multiple doses of itraconazole, a strong CYP3A4/5 inhibitor, on the PK of ganaplacide and lumefantrine in healthy participants. This study will provide data that is relevant for advice regarding possible concomitant medications that are inhibitors of CYP3A4/5 in future clinical studies with ganaplacide and lumefantrine and for potential future labeling considerations

Timeline

Start
2021-11-18
Primary completion
2022-05-13
Completion
2022-05-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Ganaplacide Small molecule 400 mg Oral
Subject Itraconazole Small molecule 200 mg Oral
Subject lumefantrine Small molecule 480 mg Oral

Indications